Journal of Clinical Oncology, Vol 9, 1157-1162, Copyright © 1991 by American Society of Clinical Oncology
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study
JK Weick, J Crowley, RB Natale, BL Hom, S Rivkin, CA Coltman Jr, SA Taylor and RB Livingston
Cleveland Clinic Foundation, OH.
Six hundred eighty assessable patients with measureable stage III M1,
non-small-cell lung cancer (NSCLC) were randomized to one of five treatment
arms including cisplatin, etoposide (VP-16) +/- methylglyoxal
bisguanylhydrazone (MGBG; PVp, PVpM); cisplatin, vinblastine (PVe); or PVe
alternating with vinblastine, mitomycin (PVeMi); or fluorouracil,
vincristine, mitomycin/cyclophosphamide, doxorubicin, cisplatin (FOMi/CAP).
The overall response rate was 20% with 3% complete responses and 17%
partial remissions. The duration of these responses was not statistically
different by treatment regimen and varied from 2.7 months to 5.0 months.
The overall median survival for all patients was 5.3 months and is not
different by treatment. Toxicity was greater in PVpM. The similarity of
results for response, duration of response, and survival does not establish
the superiority of any of these platinum-based regimens for standard
clinical usage.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C.-R. Chien and M.-S. Lai
Trends in the Pattern of Care for Lung Cancer and Their Correlation With New Clinical Evidence: Experiences in a University-Affiliated Medical Center
American Journal of Medical Quality,
November 1, 2006;
21(6):
408 - 414.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Govindan, J. Crowley, L. Schwartzberg, P. Kennedy, C. Williams, B. Ekstrand, A. Sandler, D. Jaunakais, V. Bolejack, and R. Ghalie
Phase II Trial of Bexarotene Capsules in Patients With Advanced Non-Small-Cell Lung Cancer After Failure of Two or More Previous Therapies
J. Clin. Oncol.,
October 20, 2006;
24(30):
4848 - 4854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Villalona-Calero, P. Ritch, J. A. Figueroa, G. A. Otterson, R. Belt, E. Dow, S. George, J. Leonardo, S. McCachren, G. L. Miller, et al.
A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-{alpha}, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res.,
September 15, 2004;
10(18):
6086 - 6093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Freidlin, O. S. Breathnach, and B. E. Johnson
A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer
Clin. Cancer Res.,
March 1, 2003;
9(3):
917 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. S. Breathnach, B. Freidlin, B. Conley, M. R. Green, D. H. Johnson, D. R. Gandara, M. O'Connell, F. A. Shepherd, and B. E. Johnson
Twenty-Two Years of Phase III Trials for Patients With Advanced Non-Small-Cell Lung Cancer: Sobering Results
J. Clin. Oncol.,
March 15, 2001;
19(6):
1734 - 1742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. White, S. Cheeseman, N. Thatcher, H. Anderson, B. Carrington, S. Hearn, G. Ross, and M. Ranson
Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res.,
March 1, 2000;
6(3):
868 - 873.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.-A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, C. Papadimitriou, A. Agelidou, et al.
Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial
J. Clin. Oncol.,
March 1, 1999;
17(3):
914 - 914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sauter, A. J. Wozniak, and G. Giaccone
Chemotherapy of Advanced Non–Small-Cell Lung Cancer: ""Those Who Cannot Remember the Past Are Condemned to Repeat It""
J. Clin. Oncol.,
February 1, 1999;
17(2):
730 - 730.
[Full Text]
[PDF]
|
|
|
|
